Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 for the management of fibromyalgia, with the ...

Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining for more than six months in patients with major ...

Ocugen’s AAV gene therapy, OCU410, has demonstrated its capacity to reduce geographic atrophy (GA)-associated lesion growth in the Phase II ArMaDa trial. Image credit: VectorsMarket via ...

QPS executive vice-president Derek Grimes. Credit: QPS Holdings / Business Wire. US-based contract research organisation QPS Holdings (QPS) has implemented a new clinical trial pharmacovigilance ...

In a paper published in Nature Scientific Reports, the UK Biobank was used to better understand how the risk of stroke is ...

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the J.P. Morgan Healthcare ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

An independent data monitoring committee has advised Akeso to submit a sNDA to the NMPA for cadonilimab’s approval in gastric ...

Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced ...

During a presentation at the J. P. Morgan Healthcare Conference 2026, Roche Pharma CEO Teresa Graham, projected confidence in the ability of Roche’s portfolio of marketed products to deliver growth ...

CEO Ugur Sahin is overseeing a significant strategic pivot to oncology in a bid to boost revenues. Photo by Florian Gaertner/Photothek via Getty Images. BioNTech aims to have multiple commercialised ...